Align Technology, Inc. announced on November 17, 2026, that its Board of Directors has appointed Paul J. Clancy, 65, to the Board, effective immediately. The Company also appointed Ian Bell, 56, to the Board, effective December 10, 2026. The appointments increase the size of the Board from 11 to 12 directors, and subsequently to 13 directors prior to Mr. Bell’s start date.
Paul Clancy is a biopharmaceutical executive and former Executive Vice President and Chief Financial Officer of Alexion Pharmaceuticals and Biogen. He brings over 30 years of experience in the biotechnology and pharmaceutical industries. Prior to his roles at Alexion and Biogen, Mr. Clancy spent 13 years at PepsiCo in finance and strategy positions. He currently serves on the boards of Incyte Corporation and Sionna Therapeutics, Inc., and is an Executive Fellow at Harvard Business School.
Ian Bell is the Senior Vice President and Chief Operating Officer of Alcon Inc., overseeing commercial, manufacturing, quality, and regulatory operations. Previously, he served as President of Alcon’s Europe, Middle East, and Africa region. Mr. Bell began his career at GlaxoSmithKline and held senior leadership positions at Hospira and Allergan.
Both directors will participate in the Company’s compensation program for non-employee directors, with annual retainers and equity grants prorated based on their service dates. The Company expects Mr. Clancy and Mr. Bell to stand for election at the next annual meeting of stockholders, scheduled for May 2027. The Board will temporarily expand to 13 members until December 31, 2026, when the previously announced retirement of Mr. C. Raymond Larkin, Jr. will reduce the count to 12.